Company Overview: With its separation from GSK in 2022, Haleon Consumer Healthcare became an independent company, one of the pioneers in the market. The business operates on a premise of introducing a new perspective for better health and offers products in various categories such as vitamins, oral health, pain relievers, respiratory and bowel undertakings. In 2023, Haleon kept advancing in its position committing to an aggressive strategy that targets sustainable growth and creation of long-term value for its stakeholders.
Key Financial Information:
| Category | Details |
|---|---|
| Company Net Worth | £5.2 billion (as of 2023) |
| Total Assets | £35.7 billion |
| Total Liabilities | £20.8 billion |
| Revenue | £11.3 billion (2022: £10.9 billion) |
| Operating Profit | £2.0 billion (2022: £1.8 billion) |
| Adjusted Operating Profit | £2.5 billion (2022: £2.5 billion) |
| Net Debt/Adjusted EBITDA | 3.0x (reduced from 3.6x in 2022) |
| Free Cash Flow | £1.6 billion (2022: £1.6 billion) |
Holdings by Category:
| Category | Revenue Contribution | Details |
|---|---|---|
| Oral Health | 28% | Haleon holds the top position in sensitivity care with Sensodyne and the second position in gum health with parodontax. |
| Pain Relief | 23% | Haleon is the global market leader in this category, dominating with a significant market share. |
| Vitamins, Minerals, Supplements (VMS) | 15% | This highly fragmented category sees Haleon as a key player, contributing 15% of the company’s revenue. |
| Respiratory Health | 15% | A fragmented global market where Haleon holds a strong position, contributing significantly to overall revenue. |
| Digestive Health and Other | 19% | Haleon leads in digestive health, particularly in immediate-relief antacids, solidifying its presence in this sector. |
AUDITED FINANCIAL STATEMENTS: 70 The audited financial statements of Haleon as at 2023 include a comprehensive set of the companys operational indicators such as income statement, cash flow statement and balance sheet. Key investments are in oral health, pain relief and various health related categories, top 50 holdings are enclosed.
Consolidated Financial Statements: Asset and liability structure, revenue; profit of Haleon in condensed financial statements also concern current assets and current liabilities. They also serve the interest of the shareholders by providing a preliminary review of the financial conditions of the company.
Fund Performance:
| Period | Return |
|---|---|
| 1-Year | 4.1% revenue growth, driven by strong performance across key categories. |
| 5-Year | Consistent growth with a focus on expanding global market presence and product innovation. |
| 10-Year | Significant increase in market share and global reach, establishing Haleon as a leader in consumer health. |
Management’s Discussion: According to the management of Haleon, it has not only been able to make notable progress but has been able to achieve this with regard to the company’s first full year as a legally independent company. The goal during this period was to grow the business value with a long-term focus on building the fundamental business elements of operational flexibility and stakeholder value. The management voiced concern about the performance in the areas of product development including the use of e-business strategies, and increasing their market presence.
Key Personnel:
| Name | Position | Net Worth | Short Bio |
|---|---|---|---|
| Sir Dave Lewis | Chair | £15 million | Former CEO of Tesco, Lewis has extensive experience in leading large organizations, steering Haleon through its first independent year. |
| Brian McNamara | Chief Executive Officer | £12 million | With a background in consumer healthcare, McNamara is focused on driving Haleon’s global strategy and operational excellence. |
| Tobias Hestler | Chief Financial Officer | £8 million | An experienced CFO, Hestler has played a crucial role in strengthening Haleon’s financial position post-separation from GSK. |
Directors and Officers:
| Name | Position | Age | Tenure |
|---|---|---|---|
| Sir Dave Lewis | Chair | 58 | 2 years |
| Brian McNamara | Chief Executive Officer | 54 | 1 year |
| Tobias Hestler | Chief Financial Officer | 52 | 1 year |
Remuneration: Total compensation for Haleon’s senior management was almost £18 million in 2023, which was inclusive of basic salaries, short term incentives, and est. long term rewards. The long-term compensation structure has been designed such that it is in conformity with the pursuit of growth and rewarding leadership in terms of achieving set targets strategized by management.
1 Comment
Pingback: Royal mail Net worth & Annual report - Emerging Companies, Net Worth, Future UK